Avid Bioservices Inc (CDMO)

[EYEBUYSTOX]

TOG, unfortunately the company has a history of not following through with trial results. This is from December 29, 2011:

More patients had achieved EVR in the interferon-containing group by the end of the study, however based on the nature of late EVR development in the bavituximab containing arms at the very end of the 12 week trial, a longer-term evaluation is needed to adequately compare the effectiveness of bavituximab and interferon. The company plans to present full results from the study at a medical conference in 2012.

http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=636036

I guess "plans changed" as the full results were never released.

I am confident the same will happen to Dr. Yopp's liver trial data:

March 14, 2014:

I am excited about this potential combination given the new understandings about bavituximab's mechanism and I look forward to sharing the full set of data from this Phase II trial later this year."

http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=832730

So, my question is "How many times can a company state, in an official PR, that they are going to release material information within a specified time frame, not do so, and be innocent of withholding material information under Reg FD as they are allowed to buy stock at a discount under the ESPP and grant themselves options?"

It seems that "enough is enough" IMO.